Practical Guidelines Management of Graves Ophthalmopathy

Authors

  • Imam Subekti Division of Endocrinology and Metabolism, Department of Internal Medicine, Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta
  • Pradana Soewondo Division of Endocrinology and Metabolism, Department of Internal Medicine, Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta
  • Suharko Soebardi Division of Endocrinology and Metabolism, Department of Internal Medicine, Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta
  • Budiman Darmowidjojo Division of Endocrinology and Metabolism, Department of Internal Medicine, Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta
  • Dante Saksono Harbuwono Division of Endocrinology and Metabolism, Department of Internal Medicine, Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta
  • Dyah Purnamasari Division of Endocrinology and Metabolism, Department of Internal Medicine, Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta
  • Tri Juli Edi Tarigan Division of Endocrinology and Metabolism, Department of Internal Medicine, Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta
  • Wismandari Wisnu Division of Endocrinology and Metabolism, Department of Internal Medicine, Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta
  • Dicky Levenus Tahapary Division of Endocrinology and Metabolism, Department of Internal Medicine, Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta
  • Farid Kurniawan Division of Endocrinology and Metabolism, Department of Internal Medicine, Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta
  • M Sidik Division of Neuro-ophthalmology, Department of Ophthalmology, Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta
  • Syntia Nusanti Division of Neuro-ophthalmology, Department of Ophthalmology, Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta
  • Salmarezka Dewiputri Division of Neuro-ophthalmology, Department of Ophthalmology, Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta
  • Hernawita Suharko Division of Oculoplastic and Reconstruction, Department of Ophthalmology, Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta
  • Gusti G Suardana Division of Strabismus, Department of Ophthalmology, Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta
  • Indrati Suroyo Division of Head and Neck Radiology, Department of Radiology, Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta
  • Vally Wulani Division of Head and Neck Radiology, Department of Radiology, Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta
  • Alvita Dewi Siswoyo Division of Nuclear Medicine, Department of Radiology, Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta
  • Soehartati Gondhowiardjo Department of Radiotherapy, Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta
  • Henry Kodrat Department of Radiotherapy, Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta

Keywords:

Graves’ ophthalmopathy, diagnosis, management

Abstract

Graves’ ophthalmopathy is the most common extra-thyroid manifestation in patients with Graves’ disease, based on inflammatory and autoimmune conditions in orbital tissue. This practical guideline was formed by a multidiciplinary team, and is intended to provide guidance for diagnosis and management of Graves’ ophthalmopathy in daily clinical practice to improve quality of care and treatment outcome.

References

Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy. Eur Thyroid J. 2016;5:9–26.

Kartono D. Korelasi antara ketebalan otot ekstraokular pada CT scan orbita dengan derajat oftalmopati graves. FKUI. Jakarta; 2017.

Subekti I. Diagnosis dan pengelolaan oftalmopati Graves. Jakarta Endocrinology Meeting. Jakarta: Divisi Metabolik Endokrinologi, Departemen Ilmu Penyakit Dalam FKUI/RSCM; 2008. p. 30–5.

Subekti I. Hubungan TSH receptor antibody, thyroid stimulating antibody, dan thyroid blocking antibody dengan aktivitas klinis dan derajat keparahan oftalmopati graves. Fakultas Kedokteran Universitas Indonesia. Jakarta.; 2011.

Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26(10):1343–421.

Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism. Eur Thyroid J. 2018;7:167–86.

Bahn RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pr. 2011;21(6):593–646.

Bartalena L, Marcocci C, Pinchera A. Treating severe Graves’ ophthalmopathy. Baillieres Clin Endocrinol Metab. 1997;11(3):521–36.

Tu X, Dong Y, Zhang H, Su Q. Corticosteroids for Graves’ ophthalmopathy: Systematic review and meta-analysis. 2018;2018.

Kahaly GJ, Pitz S, Hommel G, Dittmar M. Randomized, Single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy. J Clin Endocrinol Metab. 2005;90(9):5234– 40.

Bartalena L, Baldeschi L, Dickinson A, et al. Consensus statement of the European Group on Graves ’ orbitopathy ( EUGOGO ) on management of GO. Eur J Endocrinol. 2008;158:273–85.

Wiersinga WM. Advances in treatment of active, moderate-to-severe Graves’ ophthalmopathy. Lancet Diabetes Endocrinol. 2017;5(2):134–42.

Stan MN, Salvi M. Rituximab therapy for Graves’ orbitopathy – lessons from randomized control trials. Eur J Endocrinol. 2017;176(2):R101-9.

Atienza-Mateo B, V.Calvo-Río, Martín-Varillas JL, Demetrio-Pablo R. Anti-IL6-receptor Tocilizumab in Graves orbitopathy. Multicenter study of 29 patients. Sci Abstr. 2018;SAT0601:1153–4.

Fleming JC, Dailey RA, Tang RA, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376(18):1748-61.

Downloads

Published

2020-02-10

How to Cite

Subekti, I., Soewondo, P., Soebardi, S., Darmowidjojo, B., Harbuwono, D. S., Purnamasari, D., Tarigan, T. J. E., Wisnu, W., Tahapary, D. L., Kurniawan, F., Sidik, M., Nusanti, S., Dewiputri, S., Suharko, H., Suardana, G. G., Suroyo, I., Wulani, V., Siswoyo, A. D., Gondhowiardjo, S., & Kodrat, H. (2020). Practical Guidelines Management of Graves Ophthalmopathy. Acta Medica Indonesiana, 51(4), 364. Retrieved from https://www.actamedindones.org/index.php/ijim/article/view/1062

Issue

Vol. 51 No. 4 (2019): Acta Medica Indonesiana

Section

CLINICAL PRACTICE

License

Copyright

The authors who publish this journal agree to the following requirements:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)
Privacy Statement

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.